Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of Monkeypox Vaccine JT118 in Healthy Adults
NCT07495202Phase 1Active, not recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- May 2026
- Primary completion
- Nov 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in mpox comparing Experimental：JT118 with Placebo :JT118 (2 arms). Primary endpoints: Solicited adverse events Incidence Rate up to 70 days, Unsolicited adverse events Incidence Rate up to 84 days and 2 more. Started May 2026; status: active, not recruiting.
02
Drugs
JT118
03
Conditions
mpox
Beyond the preview
Go deeper on NCT07495202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07495202.